Physician profile
Corine Bowman
NPI 1841241007
$1,565.40
in general payments reported to CMS, 2019-2025
17 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $134 · 2021: $251 · 2022: $396 · 2023: $209 · 2024: $72.70 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $626.40 | 2019-2023 | Symtuza |
| Amgen INC. | $150.44 | 2020-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $124.55 | 2022-2024 | Pifeltro, Delstrigo |
| Astellas Pharma US INC | $122.59 | 2025 | Veozah |
| Viiv Healthcare Company | $104.53 | 2019-2025 | Cabenuva, Dovato |
| Pfizer INC. | $73.02 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $66.86 | 2020-2025 | Airsupra |
| Supernus Pharmaceuticals, INC. | $66.22 | 2019 | |
| Xeris Pharmaceuticals, INC. | $48.30 | 2021-2022 | |
| Gilead Sciences, INC. | $30.02 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.67 | 2021 | |
| Sumitomo Pharma America, INC. | $24.32 | 2025 | Gemtesa |
| Hologic Sales and Service, LLC | $21.73 | 2021 | |
| Abbvie INC. | $21.15 | 2020 | |
| Lilly USA, LLC | $20.91 | 2025 | Mounjaro, Zepbound |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $19.53 | 2019 | |
| Evoke Pharma, INC. | $15.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corine Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.